Catalent Plans Massive Expansion at Indiana Plant

A recent FiercePharma article discussed the announcement of drug manufacturer Catalent’s plans to expand their Bloomington, Indiana facility. The company plans to spend $350 million on the project that will increase its drug substance and drug product manufacturing capacity. This includes the purchase of two new 2,000-liter single-use bioreactors, syringe-filling lines, and extra freeze-drying capacity. The company also plans to add new labs for quality control and complex automated packaging. The full expansion plan, expected to be completed in 2024, will also create 1000 jobs in Indiana.